Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial

Detalles Bibliográficos
Autores principales: Ruhnke, Leo, Röllig, Christoph, Herold, Sylvia, Sauer, Tim, Brandts, Christian H., Steffen, Björn, Schäfer-Eckart, Kerstin, Krause, Stefan W., Hänel, Mathias, Reichle, Albrecht, Scholl, Sebastian, Neubauer, Andreas, Mikesch, Jan-Henrik, Schetelig, Johannes, Stölzel, Friedrich, Kramer, Michael, Haake, Annett, Frimmel, Julia, Krämer, Alwin, Schlenk, Richard, Platzbecker, Uwe, Serve, Hubert, Baldus, Claudia D., Müller-Tidow, Carsten, Aust, Daniela, Bornhäuser, Martin, Ehninger, Gerhard, Thiede, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483343/
https://www.ncbi.nlm.nih.gov/pubmed/36779591
http://dx.doi.org/10.3324/haematol.2022.281636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483343/
https://www.ncbi.nlm.nih.gov/pubmed/36779591
http://dx.doi.org/10.3324/haematol.2022.281636

Ejemplares similares